

गोपनीय : Confidential

मिसिल स.- 8(9)/2013 डी.पी./एन पी पी ए- डीवी-II

F. No. 8(9)/2013/DP/NPPA-Div. II

कार्यवाही स. : 141/9/2013/F

Proceeding No : 141/9/2013/F

Minutes of the 141<sup>st</sup> and 9<sup>th</sup> meeting of Authority under DPCO 2013 held on 28<sup>th</sup> November, 2013 at 12.00 Noon.

The 141<sup>st</sup> meeting of the Authority which is 9<sup>th</sup> under the DPCO 2013 was held on 28<sup>th</sup> November, 2013 at 12.00 Noon under the chairmanship of Shri C. P. Singh Chairman, NPPA. The following members of the NPPA were present:-

- (i) Shri Sanjay Kumar, Member Secretary, NPPA.
- (ii) Shri K.L Prasad, Member (Ex-Officio), Adviser, Economic Division, Dept. of Economic Affairs.
- (iii) Shri. L.M.Kaushal, Director (Cost), Member (Ex-Officio), Deptt. of Expenditure, Ministry of Finance
- (iii) Shri R Chandrashekar, Deputy Drug Controller, representing the DCG(I), Department of Health.

The following officers also attended the meeting and assisted the Authority in its deliberations:-

- (i) Shri A.K. Gautam, Adviser (Cost)
- (ii) Shri A.K. Saha, Director (Overcharging)
- (iii) Shri Lalsanglur, Director (Admin. & Overcharging)
- (iv) Shri Jagdish Kumar, Director (M&E)
- (iv) Shri A.K.Khurana, Director (Pricing & OC)
- (v) Shri S. K. Bhatt, Dy. Director (Technical)
- (vi) Smt Manmohan Kaur, Dy. Director (Cost)
- (v) Shri Manish Goswami, Dy. Director (Cost)
- (vi) Shri Singh Veer Pratap, Dy. Director (Cost)
- (vii) Shri T. R. Satish Chandran, Asstt. Director (Cost)
- (viii) Shri Suneel Chopra, Consultant (Legal)



Chairman, NPPA welcomed all the members present in the meeting. The Chairman emphasised that since the price fixation work under DPCO 2013 is almost getting completed, separate agenda notes regarding the progress in Monitoring and Enforcement, Overcharging and Legal cases be prepared by the respective divisions and placed in the ensuing meetings of the NPPA on a regular basis for discussions, decision and advice if any.

**Agenda Item no. 1**

1.0 Members of the Authority who participated in the 140<sup>th</sup> and 8<sup>th</sup> Meeting under DPCO, 2013 confirmed the minutes of the meeting.

**2 Action Taken Report:**

2.0 Noted.

**Agenda Item no. 3:**

3.0 The Authority had detailed deliberations regarding the price fixation of scheduled formulations under DPCO, 2013 relating to 18 cases proposed in the Agenda and noted that the price fixation under the present proposal was made after re-verification of data from IMS Health and also the data furnished by the manufacturers. The Authority also recalled the observations during the 1<sup>st</sup> meeting and noted that NPPA is constrained to fix the ceiling price based on the "available data" at present. The data available on the internet also may be inadequate. Moreover, the MAT value of different manufactures is also not available from the data available through internet search. Therefore, NPPA has taken a view that initially the prices may be worked out based on the IMS Health / and other available data and later on the notified ceiling prices may be revisited in extraordinary circumstances and in public interest at large, if called for.

3.1 The Authority considered and approved the prices of 6 formulation packs for fixing / notifying the ceiling price under para 4 of DPCO, 2013 based on the data furnished by IMS Health and companies. A Statement showing the prices approved and percentage of decrease from the highest price in the zone of consideration in respect of each medicine is enclosed as Annexure - A.



\_\_\_\_\_

3.2 The Authority considered and approved the prices of 4 formulation packs for fixing / notifying the ceiling price under para 6 of DPCO, 2013 based on the Monopoly conditions i.e where data in respect of only one company is available. A Statement showing the prices approved in respect of each such medicine is enclosed as Annexure - B.

3.3 The Authority considered the prices of the 8 formulation packs for fixing / notifying the ceiling price under para 4 of DPCO, 2013 based on the representations from some of the manufacturing companies and clarifications / revised data received from IMS Health. A Statement showing the prices so approved and percentage of decrease from the highest price in the zone of consideration in respect of each medicine are as well as earlier prices notified are enclosed as Annexure - C.

**Agenda Item no. 4:**


4.0 Noted

**Agenda Item no. 5:**

5.0 Noted and approved to extend the existing ceiling price fixed for Promethazine 5mg/5ml syrup vide S.O. no. 1552 (E) dated 14.06.2013 to Elixir formulation also. Further, it was classified that there is no change / revision made in the present ceiling price.

6.0 The Authority also directed that agenda notes regarding the price fixations based on the representations received from the companies and the revised data received from the IMS Health and companies be more elaborative in the ensuing meetings.

7.0 This issues with the approval of Chairman, NPPA.

  
29.11.13  
(Sanjay Kumar)  
Member Secretary



Annexure to the minutes for 114<sup>th</sup> meeting held on  
28.11.2013

Summary of Prices worked out based on Data furnished by IMS- Health/Companies							Annexure A		
Sl. No.	Medicines	Category	Route of Administration	Strengths	Ceiling Price excl. local taxes (Rs./unit)	Highest PTR (Rs./unit)	Lowest PTR (Rs./Unit)	% Reduction as compared to Highest PTR	
<b>Section: 8 – Antineoplastic, immunosuppressives and medicines used in palliative care</b>									
8.2: Cytotoxic medicines									
1	5-Fluorouracil	T	Injection	250 mg /5 ml	2.08	2.41	1.45	25.73%	
2	Mitomycin-C	T	Injection	10 mg	397.57	397.71	297.14	13.82%	
Added medicines									
3	Ifosfamide	T	Injection	1 gm/2ml vial	344.88	341.15	210	12.85%	
<b>Section: 13 –Dermatological medicines (Topical)</b>									
13.5: Medicines affecting skin differentiation and proliferation									
4	Glycerin	P,S,T	Solution		0.29	0.57	0.13	56.14%	
13.6: Scabicides and Pediculicides									
5	Benzyl benzoate	P,S,T	Route of Administration/ Dosage Form Lotion	25%	0.14	0.2	0.07	40%	
<b>Section: 15 –Disinfectants and antiseptics</b>									
15.1: Antiseptics									
6	Benzoin Compound	P, S, T	Tincture		0.32	0.39	0.22	28.21%	

Summary of Prices worked out based on Monopoly Conditions

Annexure B

Sl. No.	Medicines	Category	Route of Administration	Strengths	Ceiling Price excl. local taxes (Rs./unit)	Highest PTR (Rs./unit)	Lowest PTR (Rs./Unit)	% Reduction as compared to Highest PTR
<b>Section: 5 – Anticonvulsants/ Antiepileptics</b>								
1	Phenyloin Sodium	P, S, T	Syrup	100mg	0.77	0.74	0.74	10.68%
<b>Section: 12 –Cardiovascular medicines</b>								
<b>12.3: Antihypertensive medicines</b>								
2	Nifedipine	S, T	Tablets	20mg	0.32	0.33	0.33	15.52%
<b>Section: 13 –Dermatological medicines (Topical)</b>								
<b>13.6: Scabicides and Pediculicides</b>								
<b>Added Medicines</b>								
3	Permethrin	S, T	Lotion	1%	0.90	1.09	1.09	28.08%
<b>Section: 15 –Disinfectants and antiseptics</b>								
<b>15.2: Disinfectants</b>								
4	Potassium Permanganate	P, S, T	Crystals for solution		0.38	0.73	0.37	40.51%

Summary of Prices worked out based on Representations

Annexure C

Sl. No.	Medicines	Category	Route of Administration	Strengths	Calling Price excl. local taxes (Rs./unit)	Highest PTR (Rs./unit)	Lowest PTR (Rs./unit)	Reduction as compared to Highest PTR	
Section: 1 - Anaesthesia									
1.1 General Anesthetics and Oxygen									
Added Medicines									
1	Propofol	P, S, T	Injection	1% oil suspension	8.84	11.45	4.40	34.89%	Revision of SO 1545(E) dated 14.06.13, R. 7.94
Section: 2 - Analgesics, Antipyretics, Nonsteroidal Anti-inflammatory Medicines, Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders									
2.1: Non-Opoid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines									
2	Paracetamol	P, S, T	Injection	150 mg/ml	3.43	3.81	1.39	22.31%	Revision of SO 1553(E) dated 14.06.13, R. 3.29
3	Paracetamol	P, S, T	Suppository	80 mg	6.96	8.38	3.61	28.40%	Revision of SO 1556(E) dated 14.06.13, R. 4.88
4	Paracetamol	P, S, T	Suppository	170 mg	8.07	8.38	5.53	15.95%	Revision of SO 1557(E) dated 14.06.13, R. 5.95
Section: 10 - Medicines affecting the blood									
10.1: Antianemia medicines									
5	Folic Acid	P, S, T	Tablets	5mg	1.47	1.9	0.3	38.02%	Revision of SO 1620(E) dated 14.06.13, R. 1.15
Section: 12 - Cardiovascular medicines									
12.5: Antithrombotic medicines									
6	Urokinase	T	Injection	500,000 IU/ml	2460.97	3053.4	1206.67	29.67%	Revision of SO 1640(E) dated 14.06.13, R. 2028.57
Section: 16 - Diuretics									
7	Mannitol	P, S, T	Injection	10%	0.23	0.20	0.18	2.50%	Revision of SO 2250(E) dated 21.07.13, R. 0.66
Section: 21 - Ophthalmological Preparations									
21.5: Mydratics									
8	Homatropine	P, S, T	Drops	2%	5.44	6.05	2.34	22.52%	Revision of SO 1678(E) dated 14.06.13, R. 5